MRl of prostate cancer antigen expression for diagnosis and lmmunotherapy

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Ren, Jing ^a   Wang, Fang ^b   Wei, Guangquan ^a   Yang, Yong ^a   Liu, Ying ^a   Wei, Mengqi ^a   Huan, Yi ^a   Larson, Andrew C ^c   Zhang, Zhuoli ^a,c  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GOLD NANOPARTICLE; MAGNETITE NANOPARTICLE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 7F5; PROSTATE STEM CELL ANTIGEN; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER TISSUE; CONTROLLED STUDY; DRUG BINDING; DRUG DISTRIBUTION; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE ADENOCARCINOMA; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, IMMOBILIZED; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; FERRIC COMPOUNDS; GOLD; GPI-LINKED PROTEINS; HUMANS; IMMUNOTHERAPY; MAGNETIC RESONANCE IMAGING; MALE; METAL NANOPARTICLES; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR IMAGING; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA; MUS;

EID: 84862987909     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038350     Document Type: Article

References (40)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Damber JE, Aus G, (2008) Prostate cancer. Lancet 371: 1710-1721.
3. Jani AB, Hellman S, (2003) Early prostate cancer: clinical decision-making. Lancet 361: 1045-1053.
4. Gronberg H, (2003) Prostate cancer epidemiology. Lancet 361: 859-864.
5. Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, et al. (2009) Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 27: 5431-5438.
6. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, et al. (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96: 879-882.
7. Campoli M, Ferris R, Ferrone S, Wang X, (2010) Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin Cancer Res 16: 11-20.
8. Ferris RL, Jaffee EM, Ferrone S, (2010) Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 28: 4390-4399.
9. Kiessling A, Fussel S, Wehner R, Bachmann M, Wirth MP, et al. (2008) Advances in specific immunotherapy for prostate cancer. Eur Urol 53: 694-708.
10. Jakobovits A, (2008) Monoclonal antibody therapy for prostate cancer. Handb Exp Pharmacol 181: 237-256.
11. Giovacchini G, Picchio M, Scattoni V, Garcia Parra R, Briganti A, et al. (2010) PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 37: 1106-1116.
12. Lapi SE, Wahnishe H, Pham D, Wu LY, Nedrow-Byers JR, et al. (2009) Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. J Nucl Med 50: 2042-2048.
13. Lepin EJ, Leyton JV, Zhou Y, Olafsen T, Salazar FB, et al. (2010) An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur J Nucl Med Mol Imaging 37: 1529-1538.
14. Olafsen T, Gu Z, Sherman MA, Leyton JV, Witkosky ME, et al. (2007) Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother 30: 396-405.
15. Turkbey B, Pinto PA, Choyke PL, (2009) Imaging techniques for prostate cancer: implications for focal therapy. Nat Rev Urol 6: 191-203.
16. Turkbey B, Albert PS, Kurdziel K, Choyke PL, (2009) Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol 192: 1471-1480.
17. Beissert M, Lorenz R, Gerharz EW, (2008) [Rational imaging in locally advanced prostate cancer]. Urologe A 47: 1405-1416.
18. Eyal E, Bloch BN, Rofsky NM, Furman-Haran E, Genega EM, et al. (2010) Principal component analysis of dynamic contrast enhanced MRI in human prostate cancer. Invest Radiol 45: 174-181.
19. Huang HC, Chang PY, Chang K, Chen CY, Lin CW, et al. (2009) Formulation of novel lipid-coated magnetic nanoparticles as the probe for in vivo imaging. J Biomed Sci 16: 86.
20. Li Z, Jian L, Wang H, Cui Y, (2007) Flow injection chemiluminescent determination of clenbuterol using GoldMag particles as carrier. Food Addit Contam 24: 21-25.
21. Islam T, Josephson L, (2009) Current state and future applications of active targeting in malignancies using superparamagnetic iron oxide nanoparticles. Cancer Biomark 5: 99-107.
22. Thorek DL, Tsao PY, Arora V, Zhou L, Eisenberg RA, et al. (2010) In vivo, multimodal imaging of B cell distribution and response to antibody immunotherapy in mice. PLoS One 5: e10655.
23. Farrell E, Wielopolski P, Pavljasevic P, Kops N, Weinans H, et al. (2009) Cell labelling with superparamagnetic iron oxide has no effect on chondrocyte behaviour. Osteoarthritis Cartilage 17: 961-967.
24. Long CM, van Laarhoven HW, Bulte JW, Levitsky HI, (2009) Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes. Cancer Res 69: 3180-3187.
25. Chao X, Guo L, Zhao Y, Hua K, Peng M, et al. (2010) PEG-modified GoldMag nanoparticles (PGMNs) combined with the magnetic field for local drug delivery. J Drug Target 13: 13.
26. Chao X, Shi F, Zhao YY, Li K, Peng ML, et al. (2010) Cytotoxicity of Fe3O4/Au composite nanoparticles loaded with doxorubicin combined with magnetic field. Pharmazie 65: 500-504.
27. Bulte JW, Kraitchman DL, (2004) Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed 17: 484-499.
28. Mandal M, Kundu S, Ghosh SK, Panigrahi S, Sau TK, et al. (2005) Magnetite nanoparticles with tunable gold or silver shell. J Colloid Interface Sci 286: 187-194.
29. Meldrum FC, Heywood BR, Mann S, (1992) Magnetoferritin: in vitro synthesis of a novel magnetic protein. Science 257: 522-523.
30. Cui Y, Wang Y, Hui W, Zhang Z, Xin X, et al. (2005) The synthesis of GoldMag nano-particles and their application for antibody immobilization. Biomed Microdevices 7: 153-156.
31. Wang X, Tao G, Meng Y, (2009) A novel CdSe/CdS quantum dot-based competitive fluoroimmunoassay for the detection of clenbuterol residue in pig urine using magnetic core/shell Fe3O4/Au nanoparticles as a solid carrier. Anal Sci 25: 1409-1413.
32. Wang J, Sun Y, Wang L, Zhu X, Zhang H, et al. (2010) Surface plasmon resonance biosensor based on Fe3O4/Au nanocomposites. Colloids Surf B Biointerfaces 81: 600-606.
33. Joung JY, Cho KS, Kim JE, Seo HK, Chung J, et al. (2010) Prostate stem cell antigen mRNA in peripheral blood as a potential predictor of biochemical recurrence in high-risk prostate cancer. J Surg Oncol 101: 145-148.
34. Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, et al. (2003) Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 30: 667-676.
35. Raff AB, Gray A, Kast WM, (2009) Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett 277: 126-132.
36. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, et al. (1998) Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A 95: 1735-1740.
37. Zhao Z, Liu J, Li S, Shen W, (2009) Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia. Prostate 69: 1292-1302.
38. Jin H, Lv S, Yang J, Wang X, Hu H, et al. (2011) Use of microRNA Let-7 to control the replication specificity of oncolytic adenovirus in hepatocellular carcinoma cells. PLoS One 6: e21307.
39. Schoffelen R, van der Graaf WT, Franssen G, Sharkey RM, Goldenberg DM, et al. (2010) Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice. J Nucl Med 51: 1780-1787.
40. Bouchelouche K, Capala J, (2010) 'Image and treat': an individualized approach to urological tumors. Curr Opin Oncol 22: 274-280.